UY39206A - Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus - Google Patents

Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus

Info

Publication number
UY39206A
UY39206A UY0001039206A UY39206A UY39206A UY 39206 A UY39206 A UY 39206A UY 0001039206 A UY0001039206 A UY 0001039206A UY 39206 A UY39206 A UY 39206A UY 39206 A UY39206 A UY 39206A
Authority
UY
Uruguay
Prior art keywords
treatment
parapoxvirus
conditioning
coronavirus infections
coronavirus
Prior art date
Application number
UY0001039206A
Other languages
English (en)
Inventor
Daniela Paulsen Dr
Alexander Birkmann Dr
Peter Lischka Dr
Tamara Pfaff Dr
Holger Zimmermann Dr
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of UY39206A publication Critical patent/UY39206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al tratamiento de infecciones por coronavirus y a la preparación de sujetos para tal infección mediante la administración de un parapoxvirus. Este tratamiento tiene el propósito de asistir al sistema inmunológico en el combate del virus y de esta forma prevenir y aliviar los síntomas de la enfermedad por coronavirus.
UY0001039206A 2020-05-08 2021-05-10 Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus UY39206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20173670.9A EP3906970B1 (en) 2020-05-08 2020-05-08 Parapoxvirus for conditioning and treatment of coronavirus infections

Publications (1)

Publication Number Publication Date
UY39206A true UY39206A (es) 2021-07-30

Family

ID=70680251

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039206A UY39206A (es) 2020-05-08 2021-05-10 Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus

Country Status (27)

Country Link
US (1) US20220401553A1 (es)
EP (2) EP3906970B1 (es)
JP (1) JP2023525269A (es)
KR (1) KR20230008703A (es)
CN (1) CN115003329A (es)
AR (1) AR122044A1 (es)
AU (1) AU2021267148A1 (es)
BR (1) BR112022022635A2 (es)
CA (1) CA3173998A1 (es)
CR (1) CR20220569A (es)
DK (1) DK3906970T3 (es)
EC (1) ECSP22085708A (es)
ES (1) ES2926807T3 (es)
HR (1) HRP20221110T1 (es)
HU (1) HUE060482T2 (es)
IL (1) IL297983A (es)
LT (1) LT3906970T (es)
MX (1) MX2022013979A (es)
PE (1) PE20230459A1 (es)
PL (1) PL3906970T3 (es)
PT (1) PT3906970T (es)
RS (1) RS63635B1 (es)
SI (1) SI3906970T1 (es)
TW (1) TWI796688B (es)
UY (1) UY39206A (es)
WO (1) WO2021224503A1 (es)
ZA (1) ZA202210585B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940707B (zh) * 2022-04-19 2023-07-18 中国医学科学院病原生物学研究所 Rae1-Nup98特异性结合多肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500320T1 (de) * 2003-08-18 2011-03-15 Amsterdam Inst Of Viral Genomics B V Coronavirus, nukleinsäure, protein, verfahren zur erzeugung der impfstoffe, medikamente und diagnostika
CN1984666A (zh) * 2004-07-13 2007-06-20 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
TW201919675A (zh) 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
CN112867505B (zh) * 2018-09-20 2024-10-01 勃林格殷格翰动物保健有限公司 经修饰的pedv刺突蛋白

Also Published As

Publication number Publication date
ZA202210585B (en) 2023-06-28
WO2021224503A1 (en) 2021-11-11
EP4146262A1 (en) 2023-03-15
IL297983A (en) 2023-01-01
LT3906970T (lt) 2022-10-10
EP3906970A1 (en) 2021-11-10
US20220401553A1 (en) 2022-12-22
CN115003329A (zh) 2022-09-02
PT3906970T (pt) 2022-08-23
PE20230459A1 (es) 2023-03-10
JP2023525269A (ja) 2023-06-15
CA3173998A1 (en) 2021-11-11
CR20220569A (es) 2023-01-10
DK3906970T3 (da) 2022-09-12
PL3906970T3 (pl) 2022-10-24
AR122044A1 (es) 2022-08-03
ES2926807T3 (es) 2022-10-28
HRP20221110T1 (hr) 2022-11-25
RS63635B1 (sr) 2022-10-31
SI3906970T1 (sl) 2022-11-30
EP3906970B1 (en) 2022-07-06
KR20230008703A (ko) 2023-01-16
HUE060482T2 (hu) 2023-03-28
BR112022022635A2 (pt) 2023-05-02
TWI796688B (zh) 2023-03-21
AU2021267148A1 (en) 2022-12-01
ECSP22085708A (es) 2022-12-30
TW202207980A (zh) 2022-03-01
MX2022013979A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
CL2020000498A1 (es) Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920)
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
CO6761399A2 (es) Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
BRPI1006266A2 (pt) adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato
ECSP22085708A (es) Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus
ES2525009T3 (es) Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
ES2544153B1 (es) Uso de un hidrolizado de caseína como agente antiviral
BR112014003278A2 (pt) vacinas para influenza h5
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
CO2019009216A2 (es) Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas
BR112017009193A2 (pt) método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta